| abstract |
The present invention provides compositions and improved methods for treating cancer using IL-2 immunotherapy. The method of the present invention comprises administering the fusion protein of SEQ ID NO: 1 at a dose of about 6 μg/kg/day to about 70 μg/kg/day, preferably at least about 6 μg/kg/day to about 15 μg/kg/day. administering to the patient in a dose, or a corresponding fixed daily dose, e.g., on an adult human basis, e.g., based on an average of about 60 to about 70 kg, or on a child basis, from about 12 kg to about 50 kg or more; wherein administration results in a dose-dependent increase in circulating NK cells and CD8+ cells in the patient in the absence of a dose-dependent increase in circulating immunosuppressive T regulatory (Treg) cells, preferably an increase in circulating NK cells and CD8+ cells is greater compared to the increase in circulating T Treg cells. |